Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.17 EUR | +2.37% | +0.49% | -18.54% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an expected P/E ratio at 38.79 and 19.14 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.54% | 1.77TCr | - | ||
+54.67% | 81TCr | C+ | ||
+44.25% | 65TCr | B | ||
-6.51% | 35TCr | C+ | ||
+21.75% | 34TCr | B- | ||
+10.38% | 30TCr | C+ | ||
+18.09% | 25TCr | B+ | ||
+2.25% | 23TCr | A+ | ||
+13.00% | 22TCr | B- | ||
+9.38% | 17TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4503 Stock
- YPH Stock
- Ratings Astellas Pharma Inc.